Ascendis Pharma A/SNASDAQ: ASND

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD).

Lagoa Salgada selected to participate in the European Union's UNDERCOVER Project to unlock hidden critical mineral deposits at depth using cutting edge Geophysical techniques UNDERCOVER Project will employ Seismic Reflection and Refraction, Magnetotellurics (MT), Gravity and Magnetic Surveys, Electromagnetic (EM) Surveys, and Joint Inversion Techniques to delineate potential deposits of critical minerals at depth The two-year program is fully funded by the EU under its Horizon Program and is expected to commence in Q1 2025 TORONTO, ON / ACCESSWIRE / September 30, 2024 / Ascendant Resources Inc. (TSX:ASND), through its Portuguese subsidiary, Redcorp Empreendimentos Mineiros Lda is pleased to announce its award of EU funding through its participation in the UNDERCOVER project. The project aims to advance mineral exploration by applying state-of-the-art geophysical technologies to uncover hidden mineral deposits at significant depths.

COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 300,000 ADSs at the public offering price, less the underwriting commissions.

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

Ascendis Pharma (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ascendis Pharma A/S ASND released topline data on Monday from a trial that included 84 children with achondroplasia, a genetic disorder that causes dwarfism and disproportionate short stature.

–   U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults

Shares of Ascendis Pharma are under pressure as the company posted a big Q2 revenue miss, driven by a decision to significantly reduce the net price of Skytrofa. Demand for Skytrofa remains strong and quarterly net sales could go back to new highs in the fourth quarter, if not in Q3 already. Yorvipath's U.S. price is above expectations and could increase long-term sales, but initial uptake and payer pushback need monitoring.

Tuesday, Ascendis Pharma A/S ASND reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ago.